Loading
Organon & Co. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 13 Nov 2025.
Organon & Co.: what insiders have been doing
Every trade that managers of Organon & Co. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Oss, United States. It was founded in 1923. Over the twelve months to 18 October 2026, the company's managers filed 75 filings, from 12 insiders.
Both sides are active: 1 purchase worth €433k and 1 sale worth €174k, from 1 insider and 1 insider respectively. The net balance comes to €259k on the buying side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The buyers include 1 chief executive. One trade stands out by size: a purchase of €433k from Cox Carrie Smith, disclosed on 13 November 2025.
The latest purchase dates back some time: it was published 339 days ago, on 13 November 2025. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade.
For context, the typical company on the same exchange (median of 5,810 companies) published 19 filings over the same period, against 75 filings here. Looking back to 2021, when coverage begins, insiders filed 9 purchases and 1 sale. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 6.22 bn USD and net income at 187.0 m USD, and the dividend at 0.34 USD per share.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
212
Thresholds
n/a
Buy Volume
€1M
9 ops. · all time
Sell Volume
€173,706
1 ops. · all time
Who traded when
BuySaleCox Carrie Smith2 buys
Aaron Falcione1 buy
Ali Kevin1 buy
Daniel Karp1 buy
Juliana Papa Drinane1 sale
Kirke Weaver1 buy
+1 other insider
Since the insiders bought
- -6.2%Entry US$7.53 · Close at T+90 US$7.06
- +48.0%Entry US$9.02 · Close at T+365 US$13.35
- +48.0%Entry US$9.02 · Close at T+365 US$13.35
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 7,055 of 24,148 companies
61.9
score / 100
Value70
Quality54
FCF yld11%
Earn yld5.2%
EV/EBITDA9.5x
ROE24%
Gross mgn53%
Net mgn3.0%
Debt/EBITDA6.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$13.77
Analyst consensus
4 analysts3.20/5
US$8.00Target US$11.25(-18%)US$14.00
Income statement
RevenueUS$6.2B
Gross profitUS$3.3B53% margin
EBITDAUS$1.3B21% margin
Net incomeUS$187M3.4% margin
Valuation
PER (trailing)17.7x
PER (forward)3.8x
P/Book3.6x
Beta1.54
Balance sheet & cash
Market capUS$3.6B
Total debtUS$8.6B
Free Cash FlowUS$384M
Debt / Equity850%
Profitability & ownership
ROE24.0%
ROA5.7%
% insiders0.5%
% institutions84.7%
Last declaration on 12 August 2026
Declarations212 total
11,519 shares0Common StockSEC:0001628280-26-056061:0
4,134 shares@ US$13.620.0015% mcap36.2% of flowCommon StockSEC:0001628280-26-056061:1
14,761 shares@ US$13.570.0055% mcap100.0% of flowCommonSEC144:0001950047-26-007707
14,761 shares@ US$13.570.0055% mcap78.0% of flowCommon StockSEC:0001628280-26-053306:0
11,338 shares0Common StockSEC:0001628280-26-023180:0
16,789 shares0Common StockSEC:0001628280-26-023127:2
4,606 shares0Common StockSEC:0001628280-26-023143:0
8,394 shares0Common StockSEC:0001628280-26-023143:2
6,201 shares0Common StockSEC:0001628280-26-023146:0
12,312 shares0Common StockSEC:0001628280-26-023146:2
12,047 shares0Common StockSEC:0001628280-26-023157:0
21,546 shares0Common StockSEC:0001628280-26-023157:2
6,555 shares0Common StockSEC:0001628280-26-023166:0
12,312 shares0Common StockSEC:0001628280-26-023166:2
13,431 shares0Common StockSEC:0001628280-26-023188:0
6,378 shares0Common StockSEC:0001628280-26-023209:0
4,252 shares0Common StockSEC:0001628280-26-023139:0
4,820 shares@ US$5.7017.6% of flowCommon StockSEC:0001628280-26-023188:1
2,185 shares@ US$5.704.8% of flowCommon StockSEC:0001628280-26-023209:1
3,451 shares@ US$5.707.6% of flowCommon StockSEC:0001628280-26-023209:3
6,715 shares0Common StockSEC:0001628280-26-023180:2
7,795 shares0Common StockSEC:0001628280-26-023127:0
3,834 shares@ US$5.7021.6% of flowCommon StockSEC:0001628280-26-023150:3
1,212 shares@ US$5.7025.8% of flowCommon StockSEC:0001628280-26-023139:1
3,554 shares@ US$5.7023.1% of flowCommon StockSEC:0001628280-26-023180:1
25 of 212 declarations
About Organon & Co.
Organon & Co. (NYSE: OGN) is a U.S.-listed healthcare company headquartered in Jersey City, New Jersey, United States. It was created in 2021 as a spin-off from Merck, and it has since built a business model centered on women’s health, supported by a portfolio of biosimilars and established brands. For investors, Organon is best viewed as a specialty pharmaceutical company with a defensive profile, but also with meaningful exposure to pricing pressure, loss of exclusivity, and commercial execution.
The company’s operations are organized into three main portfolios: Women’s Health, Biosimilars, and Established Brands. Women’s Health is Organon’s strategic core and includes contraceptive and fertility products such as Nexplanon, NuvaRing, Follistim AQ, and Elonva. The Biosimilars portfolio spans immunology and oncology-related therapies, including Hadlima, Renflexis, Ontruzant, Tofidence, as well as newer U.S. launches such as Bildyos and Bilprevda. The Established Brands segment includes products across dermatology, respiratory, cardiovascular, and non-opioid pain management, with brands such as Emgality and Vtama among the better-known assets. This mix gives Organon both a focus franchise and a broad base of mature products.
Read moreShow less
Geographically, Organon has a highly international footprint. The company distributes products in more than 140 countries and territories, and most of its revenue is generated outside the United States. That global reach is an advantage because it diversifies the business across markets, but it also introduces exposure to foreign exchange movements, local reimbursement systems, and regulatory complexity. In competitive terms, Organon is differentiated by its leadership ambitions in women’s health, where it benefits from brand recognition and established commercial relationships, while still facing strong generic and biosimilar competition in other parts of the portfolio.
Recent developments are important for investors following the stock. Organon reported full-year 2025 revenue of about $6.2 billion and emphasized balance-sheet improvement and deleveraging actions. The company also completed the divestiture of the JADA system in January 2026. In addition, management disclosed that its audit committee is reviewing certain prior-year biosimilar purchasing timing matters. Most notably, in April 2026, Organon announced a definitive agreement to be acquired by Sun Pharma in an all-cash transaction, making this a particularly significant event for OGN on the NYSE in the United States.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
